Rocket


Overview
Financials
News + Filings
IR Vault
Key Docs
Charts
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
CC transcript
Auditor change
Appointed CFO
SCICLONE PHARMACEUTICALS INC (SCLN) Create: Alert

All | News | Filings
Date FiledTypeDescription
04/19/2011 MW SciClone Acquires NovaMed Pharmaceuticals Further Establishing It as a Leading China-Focused Specialty Pharmaceutical Company
03/31/2011 MW SciClone Pharmaceuticals Provides Fourth Quarter and Year End 2010 Results and 2011 Guidance
03/31/2011 MW SciClone Pharmaceuticals to Provide Financial Update on April 1
03/16/2011 MW SciClone Reports Preliminary Financial Results for the Fourth Quarter and Year End 2010
03/01/2011 MW SciClone Pharmaceuticals to Present at Two Investor Conferences in March
02/28/2011 MW SciClone Pharmaceuticals to Report Fourth Quarter and Year-End Results for 2010 on March 16
02/08/2011 MW SciClone Pharmaceuticals to Present at BIO CEO & Investor Conference
01/11/2011 MW SciClone Initiates Phase 2b Study of SCV-O7 for Treatment of Oral Mucositis
12/15/2010 MW SciClone Announces Topline Results From Phase 2b Clinical Trial of SCV-07 for Treatment of Chronic Hepatitis C
11/10/2010 MW SciClone Pharmaceuticals to Present at Two Investor Conferences in November
11/08/2010 MW SciClone Reports Financial Results for the Third Quarter of 2010 and Provides Updated Guidance for the Full Year
10/12/2010 MW SciClone Announces Continued Topline Growth and Strong Cash Position in the Third Quarter of 2010
10/05/2010 MW Debt Financing Facility Increased to $15 Million
09/29/2010 MW SciClone Identifies Unique Genetic Markers Associated With Patient Response to SCV-07 Treatment in Oral Mucositis
09/13/2010 MW SciClone Pharmaceuticals to Present at Two Investor Conferences in September
09/08/2010 MW Kaplan Fox Files Securities Class Action on Behalf of Purchasers of SciClone Pharmaceuticals, Inc. Common Stock; Reminds Investors of October 12, 2010 Lead Plaintiff Motion Deadline
08/19/2010 MW Brower Piven Encourages Investors Who Have Losses in Excess of $50,000 From Investment in SciClone Pharmaceuticals, Inc. to Inquire About the Lead Plaintiff Position in Securities Fraud Class Action Lawsuit Before the October 12, 2010 Lead Plaintiff Deadline
08/10/2010 MW Analyst Research on Today's Biggest Market Movers -- Dell, Microsoft, SciClone and Almaden
08/09/2010 MW SciClone Reports Financial Results for the Second Quarter of 2010 and Provides Updated Guidance for the Full Year
07/29/2010 MW SciClone Pharmaceuticals to Present at the BMO Capital Markets 10th Annual Focus on Healthcare Conference on August 5
07/26/2010 MW SciClone Pharmaceuticals to Report Second Quarter 2010 Financial Results and Provide a Business Update on August 9
05/17/2010 MW SciClone Provides Clinical Program Update for SCV-07 for the Prevention of Oral Mucositis in Patients With Advanced Head and Neck Cancer
05/10/2010 MW SciClone Pharmaceuticals to Present at Two Investor Conferences in May
05/06/2010 MW SciClone Reports Financial Results for the First Quarter of 2010
04/26/2010 MW SciClone Pharmaceuticals to Report First Quarter 2010 Results on May 6
03/30/2010 MW SciClone Announces Topline Results From Phase 2 Clinical Trial of SCV-07 for Prevention of Oral Mucositis
03/24/2010 MW ondansetron RapidFilm(TM) Approved in 16 European Countries
03/02/2010 MW SciClone Reports Financial Results for the Fourth Quarter and Year End 2009 and Provides Commercial and Pipeline Updates
03/01/2010 MW SciClone Pharmaceuticals to Present at Three Investor Conferences in March

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy